The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.
Acquisitions are all the rage in the health-care sector these days, and Roche just made waves with its hostile takeover targeting a prominent gene sequencing company. In this video, David and Austin discuss whether Roche's first offer will be enough to get the deal done and if jumping into gene sequencing companies make sense for Roche or investors.
Austin Smith and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services recommend Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.